BioSight
Companies
Septerna, Inc. logo

SEPN

NASDAQSOUTH SAN FRANCISCO, CA
Septerna, Inc.

Septerna, Inc. is a clinical-stage biotech company developing small molecule therapies for immunology and rare disease indications, with lead programs including SEP-479 and SEP-631 currently advancing through preclinical and clinical development stages. The company is focused on demonstrating preclinical proof-of-concept for multiple programs while advancing regulatory filings and IND applications to support clinical advancement of its product candidates.

Price history not yet available for SEPN.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar